US Patent

US11241382 — Administration regimen of compositions of T4 thyroid hormone with high oral absorption

Method of Use · Assigned to Altergon SA · Expires 2039-09-17 · 13y remaining

Vulnerability score 70/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects new administration regimens for T4 thyroid hormone, involving alcohol-free solutions taken within 15-30 minutes of a meal.

USPTO Abstract

New administration regimens of the T4 thyroid hormone are described, characterized by the use of alcohol-free, water-glycerol solutions of said hormone, administered at short temporal distance, i.e. within less than 30 minutes, typically between 15 and less than 30 minutes, from the closest consumed meal.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3757 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid
U-3758 — Unithroid

Patent Metadata

Patent number
US11241382
Jurisdiction
US
Classification
Method of Use
Expires
2039-09-17
Drug substance claim
No
Drug product claim
No
Assignee
Altergon SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.